A randomized double‐blind controlled trial for use of tirzepatide, a dual GIP and GLP‐1 agonist, for 12 weeks in T2DM patients showed that this drug improves insulin sensitivity and atherogenic profile.56 Here, GIP is linked to type 2 diabetes mellitus.